CA2227871A1 - Mucosal delivery of polynucleotides - Google Patents

Mucosal delivery of polynucleotides Download PDF

Info

Publication number
CA2227871A1
CA2227871A1 CA002227871A CA2227871A CA2227871A1 CA 2227871 A1 CA2227871 A1 CA 2227871A1 CA 002227871 A CA002227871 A CA 002227871A CA 2227871 A CA2227871 A CA 2227871A CA 2227871 A1 CA2227871 A1 CA 2227871A1
Authority
CA
Canada
Prior art keywords
polynucleotide
composition
animal
binding protein
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002227871A
Other languages
French (fr)
Inventor
Dannie H. King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxim Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2227871A1 publication Critical patent/CA2227871A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/118Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

A composition for delivery of a polynucleotide to mucosal, neural, or other cells, comprising a GN1-binding protein and a polynucleotide in association with the binding protein; and a method for modulating immunity comprising administering the composition to an animal and expressing the polynucleotide whereby the animal generates an immune response to the product of the polynucleotide; and a method for gene therapy comprising administering to an animal a GM1-binding protein and a functional polynucleotide and expressing the polynucleotide in the animal whereby the function of the polynucleotide confers on the animal a therapeutic effect.

Description

W O 97/05267 1 PCT~US96/12041 MUCOSAL DELIVERY OF POLYNUCLEOTIDES
RELATED APPLICATIONS
This ~j,'claims priority to F 13~ ,' No. 601001527, filed July 26, 1996 under 35U.S.C. 119(e).
FIELD OF THE INVENTION
This invention relates to the delivery of r ' r 1~ to mucosal and neural tissues of ~. tcb.dl!c animals, and to other tissues or cells that display the 6M1 receptor. The r ' ~ ' i 't ~ thus delivered can be i' . genes or they can operate to modulate the immune 1~, of the animal. The - ' ' may either increase or decrease the _ ' of a ~ ' , immune response in the animal.
B~CUI:ROUND OF THE INVENTION
Mucous ' ~~ cover the exwsed surfaces of the aerodi9estive and . ~~ ~- ' tracts, the eye S ~-.a, the inner ear, and the ducts of all exocrine glands. Due to their " ' ~ . mucous ' .
- le, ~ foreign particles and invading microbes c : :~y. These ' 5 are capable of trapping 15 and d " most of the particles and microbes they ~ ~ . In addition, mucosal tissues have a ~ ' immune system. The cells of the mucosal immune system comprise the e G ' Iymphoid tissues IMALT).
MALT cells regularly e ~ le. a vast array of foreign ~ ' I A full-scale immune response against every foreign b~: :r thus IcuLd would render . ' such a simple and vital process as ingesting r U; ~ ~~~ food, for example. Therefore, the mucosal immune system must have the ability to s~ ignore 20 most foreign epitopes while it mounts a vigorous response to certain others.
The ,' of acquired 11 _ of certain foreign epitopes is known as "oral tolerance" because it was first perceived through a " ' ' s_..~iti.;~y to certain olh_.~ ;~c ' - if ingested in large enough; 3r It is now known that this "oral tolerance" can be acquired, at least i . aDI'~ and locally, by surG.,;_.,t exposure of MALT cells to some foreign Many mucosal cells are chalaclcli.cd by the relative ' of r _" '' GM1 in their plasma ' _ - GM1 is a ' - ~ ' whose lipophilic ceramide portion diffuses into and with the , ~, ' -1i~ ' bilayer of the plasma ~ ' alla' while the 'ig ' iJc-sialic acid moieties of GM1 protrude out of the ~clldJlalla and are displayed on the cell surface. GM1 is not limited to mucosal cells alone. In fact, GM1 is present at some level in many different cell types of the body, but most -' ' :'~ in neuronal ' . and ' anes of mucosal cells.
GM1 can act as a receptor in the plasma ' for proteins that bind its exposed :1ig --- ' iJc-sialic acid portion. The best known GM1 binding protein is the toxin of Vibrio choler.~e, the cholera toxin (CT). CT
consists of two types of subunits. The A1 fragment of the A subunit has ADP-G' - ylaliun activity while the B
subunit has GM1-binding activity. The holotoxin is a h-clcl~ ' s ~ _ of five B subunits and one A subunit.
The structure and function of the related E. coli heat-labile ! ' ulwJIl (LT)is quite similar to that of CT.

The ADP-M ~lali~...âctivity ând the GM1 binding of CT are both essential to the overall toxin activity of CT. Subunits of the holotoxin, whether A or B, do not ~ . dh'~ cause the toxin reaction in vivo. In the cell, the A subunit's ADP-r' ,' ~ activity transfers the ADP-ribosyl moiety of NAD to the a subunit of the guanine-~; ' ! " _ protein Gs~ the I ' ~ h ' positive regulator of adenylate cyclase.
Although the present text primarily discusses the use of GM1 binding proteins, it should be noted that "ADP-li' ,: - _ moieties" are also - . ' ' as part of the present invention as fully as if that term was used in place of the term "GM1 binding protein," as the latter term appears herein.
There are various other ADP-~ h.,: enzymes with . ' g function. For example, the I
C..I~IUI1IA;II (LT) of E. co/iis doubly similar to CT because its A and B subunits also display ADP-I ' - ,laliùll activity 10 and GM1 binding activity"~_"c~,ti.~
Because GM1 includes and displays an ~ ' ' portion, it can also be bound by numerous lectins and lectin-like ~' ' Also, because of the lipophilic nature of the ceramide portion, O GM1 is readily taken up by ' _ ~s of many cell types.
CT elicits â strong reaction by the mucosal immune system. A~ , the holotoxin or the A subunit 15 alone have been used as adjuvants to stimulate a mucosal immune reaction aoainst other selected epitopes.
S, _ to many is the CGull~ fact that CTB, when coupled to a selected epitope, has a strong ability to effect an acquired ("oral") tolerance to the delivered epitope. The B subunit alone ~rri~ delivers the coupled epitope to the proximity of the MALT, but generally does not by itself stimulate an ' of immune L "' The result of such a delivery without a stimulus of immunity is often acquired ' .
The dual ,' ~ of enhanced or ' ' ' mucosal immunity, together with the influence that the mucosal immune system has on systemic immunity, have caused cûr,~ . '' interest in the '~ ', of - ~ - ~ and methods of ll~allll~lll involving CT or CTA as adJuvants for mucosal immunity, and CTB as an initiator and mediator of acquired tolerance.
Current methods and c - rely on covalent coupling of a desired epitope to CTB for delivery of the 25 epitope to the MALT with the purpose of gaining acquired tolerance to the epitope. This scheme has been especially .;alud by those ~ - t:;,led in àdJ~ ~_ problems of allergy, allograft rejection, and ~ diseases.
Likewise, workers wishing to stimulate acquired mucosal, and possibly systemic, immunity have combined their selected antigen with CT or CTA to achieve enhanced mucosal immunity.
In both cases, the instability of the delivered protein epitope and of the coupling to CTB have been 30 ' to the ~rr~l;.L~ss and duration of the desired exposure of MALT cells to the epitope. The invention described herein add~L~es this problem in a novel way. Beyond the novelty of the solution to a ' ; , in the current state of the art, the present invention also has great utility in gene therapy a,. ' Described herein is an invention that delivers an active PO1~ULI~U ' to target cells, such as MALT cells, by - ' ~ _ or coupling the pol~.,uLl~olid~ to a GM1- or other mucosa-binding protein. The delivered molecule, 35 being a p~'~ '/ Ihle rather than a protein, has an effect in a single delivery event that can be many hundred- or ~ ' fold greater than the delivery of a single protein. This is because the active r-~- ~ JtiJe can direct, CA 0222787l l998-0l-26 W O 97/05267 PCTAUS96/12~41 encode, or ' . ;__ affect the ultimate ~ of many copies of the desired protein. Further, it can do so for hours or days if l:A~ ;oSO~ or on a r ~ basis if the rN~ stably _ dl~o into the genome of the cell to which it is delivered. Similar results can not possibly be achieved when the delivered molecule is merely a protein.
Since the invention employs binding proteins that do not only recognize mucosal cells, the invention also has utility in the field of gene therapy. The binding protein and ' _ ' of the target cell can be selected andlor , ' ' such that a i' ~ gene or other po'~ ' : ' can be faithfully and er~
delivered to the target cell. The result is either a transient ll ' :- r or a stable,, ~ D ~ mation or the target cell.
SUMMARY OF THE INVENTION
This invention ~ ' a novel approach to gtene therapy and to :, 'etiof the immune system.
The invention relates to a . - that pr"~r,se~ the ability to localize r~ ' ~N~ ' -: ' to mucosal tissues, neural tissues, and to other tissues or cells that display the GM1 receptor. The ~I ' '( : ' thus~5 delivered can be l' _ - genes or they can operate to modulate the immune ", of the animal. The ' ' may either increase or decrease the ' of a ' . immune response in the animal.
The invention is embodied in a c . for delivery of a pol~ ' : ' to mucosal cells, nervous cells, and other 1,~. ' dl~ cells and tissues. The . - 5 . ioL5 a L- " _ protein having an affinity for d~t~,.l of ~ b,dl~mucosaltissuesina ~ withanactive~vl~ ' :' Becausethe -' "_ 20 protein also has an affinity for other cell types, the v . of the invention is also effective in delivering an active ~ 1t to other selected cells and tissues as well.
A more particular - ' -' : of the invention has as the protein pr a member of the following group of r~rns? ! " g proteins: CT, CTB, LT, bacterial fimbriae proteins, animal lectins, plant lectins, and lectin-like proteins.
Z5 In a preferred - bc"I of the invention, the o _ protein is the cholera toxin of Vibrio cholerae. This Sc " L C. ' leS the use of the ' ' . which consists of A and B subunits, or O
or G__ l thereof, and also o , ' the use of a particular fragment of the toxin, - _ only of the B
(binding) subunit. Also i ' ' is the use of only the A (active) subunit, involving both ~.__ : of the A
subunit (A1 and A2) or only one fragment thereof, as well as other I ~t ' '.~yhlg ADP li' yk~ activity.
Another: h " - of the invention has as its protein v Jm~ : an 1~' ' " capable of S~ ~;r~
110_., ~, mucosal cells. In a more particular L-' I of this aspect of the invention, the 19' ' "
It~LoL~ and binds to the GM1 receptor.
Further e-5~ " of the invention relate to the F"'~ ' ti ie c . :. In one bc " :, the poi~, ' li ie is DNA. Where the p:'~, ' - is DNA, the DNA may be of genomic origin. All~llwli elt, the DNA
35 may be cDNA. A~'"- 'Iy, according to the invention, the DNA may be ~-- ' DNA. The invention Culli . ~ - - all forms of DNA as the pcl~, ' li ie r . Jr W O 97/05267 PCT~US96/12041 4-- This aspect of the invention has as a preferred - '~ DNA that contains a promoter region 3, , 'I~ linked to a coding region. The coding region may specify various protein domains. Another preferred of the invention has DNA that encodes an antisense message.
In another ' ' of the invention, the F~ ' c , is RNA. Ar- P _'~, in a preferred 5 ! '~' t, the RNA is mRNA. In another preferred e ' ' t, the RNA is In an ~d' ' ~ ' t, the RNA is a ribozyme. The invention , ' all forms of RNA as the r ~ i.le c pr The - , ~ may exist in several useful forms. All useful forms of the L , are t .'- ' in this ~ .~..; In one ~ ' Jd- t, the composition exists in the form of an atomized d-, ~ such as would be used in delivery by ~ ' ' - ~ In a preferred r ' ' t, the composition exists in the form of a ~ s-~( y, 10 whether rectal or vaginal. In another preferred ' ~ ' t, the composition exists in the form of a cream, an ointment, or a l~ llal patch.
The inventlQn ~!sQ ~ ...pl..!~ al! ways in which the nnucosa-binding pr~tein and the &ai~,.,u~ltolh~e may form the r , In a preferred e ' ~ ' t, the . , exists in the form of a mixtute ~f ~a b- " v protein and p~ wl~ The mixture may be stabilized by other ~ , If ' that exploit e' rt,u~ldli,, or 15 h~d..~' ' hll~aLliulls, or that diminish the ~rr~uli. of mucus as a barrier to delivery of the F '~ ' ' In another: ' -' I, the s. ! ~ " _ protein and the, ~ ' are !' ~ 11~ coupled to each other. In an '' ' e...L~' of the i..~ the 1- ' _ protein and the r ~ t;d~ are , ' together.
Another aspect of the invention is a method for ~ ' ' - " immunity in an animal. The first step of the ZO method is to - ' ~ ~ - to an animal in ' - a m~~osa l ' _ protein and a r ~ uti '~ encoding an ~ 19 The second step is to express the r ~ Iy ~ : - in the animal uhereby the animal g ales an immune response to the product of the prl~..u..l~o ' In one preferred: ' " I of this aspect of the invention, the - ~ ' ' is an enhanced immune response in the animal. The invention -l ~ , ' It.~ that the enhanced immune response may be mucosal, or systemic, or both 25 mucosal and systemic. An r''' ~' bc' of this aspect of the invention directs the enhanced immune response to Cu-lllaC.,~,liuil.
In another preferred ~ bc' of the invention, the ' ' is a ' ~ ~ ' ' immune I r~- The invention L ' ,' 1~5 that the ' ~ ~ ' ' immune response may be mucosal, or systemic, or both mucosal and systemic. The invention is, ~r~laLly embodied in a ' ~ ~ ' ~~ immune response for ~ - to allergens, in 30 a manner ' v- to oral tolerance. In another preferred bor' I, the ' ~ ' ' immune response is for ; ' dLiull of organ and tissue 1, , ' A further preferred ' - ' L of the invention directs the :' ~ ~ ' immune response to the ~II a~ ..l of an .A~i disease.
According to the invention, the ' ' of the immune response may be done prior to exposure to a pathogen or alleryen. The invention also ,' ~ the ' ' where it is done after exposure to the 35 pathogen or allergen. Therefore, all uses of the r ~ ~'- of the invention for the ' ' of the immune W 097/05267 PCTrUS96/12041 - response are embodied in the present I ~. . whether I ~ . ~ or F- . ~, and whether to immunize or i7~ the animal so treated.
The . of the invention may be . ' ~ ~d in a number of ways. In one ~ ' ~ ' t, the mode of - ' ~.. is nasal andlor, ' y. In a preferred b~ ' t,the mode of - ' ~ , is oral. Further preferred ' ~ ' _' the pr of the invention rectally orvaginally. All~ ,the invention is also embodied in a mode of _' ~ : i _ the ~ ~r of the invention by ' ' by _' tl i _ the pr !, ' ' ' ~ dlly, and also by administering the composition transdermally.
Another aspect of the invention is the ~ . ~ r to deliver a p ~~ - ' to any GM1 animal cell. The binding protein component of the s . ~ has an affinity for the GM1 receptor and because of the 10 affinity, delivers a r~ : to any cell ' ,' ~; " the GM1 receptor.
In one . bc ' : of this aspect of the invention, the bindiny protein is selected from the group ~
of GT, GTB, LT, LTB, bacterial fimbriae proteins, plant lectins, animal lectir.s, and lectimlike prs~eins.
In a preferred bc " :, the binding protein is either cholera holotoxin (with A and B subunits) or it is a ' i.al;.~. of the toxin, having some fragment of the toxin, either alone or in ~ ' - with other protein ~I _ In an ' Ilali.., preferred: ' ~ ' t, the binding protein of the: . ~ is an ' ' "
According to the invention, GM1 delivery of a F~ ' li.le also . .': ~ purposes of gene therapy.
As such an ' -' :, the invention discloses a method for gene therapy in an animal by ~ to an animal in ~ ' a GM1-binding protein and a r, : p~l~ ' ; ' and then i . _ the pr1~ ' liJe in cells 20 of the animal. By this method, the function of the r' H~ ~ o d~ confers on the animal a i' ~ . effect.
In a preferred e L " I of this aspect of the invention, the cells of the animal Ir ' '1~ express the delivered rl ~ pL~ U~ u''' An -' Ildli.~ preferred L-d exists when the cells of the animal are stably l,l.";.r. by the r. p~
DETAILED DESG~lrllON OF THE INVENTION
Mucosal tissues are the route of entry of many ~- ' diseases. They are also the chief sites of invasion and irritation by many allergens. This invention -' ~ases both of these medical problems. r: t, the invention provides an approach to other Di~.alll diseases and ~ via a novel method of delivering 30 pGb~ ' lidd5 to certain cells for gene therapy.
The invention makes possible the ' ' liu,, of the mucosal and systemic immune systems of ~_. ' dle animals by targeting E --' pN~ ..,lid~.5 to the cells involved in mucosal immunity. The pol~ ' li,les are then ;"l~" ' ' within these cells and are ~ ased therein. The products of the r H~ t;d~5 can either enhance or diminish the ~ n. !~ of the body's normal immune response to the epitope of choice, thus rendering the body less reactive to certain allergens, or more effective at ~ certain F ' al, . according to the pal ~ of . CA 02227871 1998-01-26 <
, . . .. .
the particular use of the invention. The ability to thus modulate the ,es~l",s~s of the immune system also relates the invention to the Il~dtl"~"L and ~ iol1 of autoimmune diseases.
Rather than delivering only one dose of a particular pul~pe~ de allergen or imm~nogen, as would be the case with a rQmrositinn COlla;aiilly ûf a mucosa-binding protein and a given polyp~,ulide, the present invention makes 5 possible a greater exposure of the target cells to a given allergen or ;~ ogen because of the fact that a single polynucleotide can direct the eA~ r of many copies of its product. The ~tieLli.~,ness of the exposure of the mucosal cells to the peptide product may also be improved because of the duration of the OA~ aaiun of the pvl~,,u~ oIide within the cell, and because of the i"~, ~ " ' origin of the pGl~ product of the active pOIylluLldrj lill~.
Because the mucosa-binding proteins of the invention will actually bind to any cells that display GM1 in sufficient crn ll: . the invention further ~o ~ s a novel mode of pQI~l ' liil~ targeting and delivery fûr gene therapy p~' ~~ Current modes of 1' ~, gene delivery are largely limited to viral capsids, cationic lipids, . .,d live viruses, and ex vivo ll_ 'c ~ Most require injection of the material in questicn. However, this invention makes possible the adr : dC of a Ih.,ru~ li.. gene or other ~ .liunal pGI'1llul~lu~,lille by means 15 of i"hd61- oral dosage, eye drops or creams, nose drops or creams, a ~pc-~;lu~i~3, enemas, douches, or llanade patches, creams, or ~ ~ Auc.d 1~, the use of the present invention for gene therapy will have special ~r~. ~;.. against diseases of mucosal tissues and neural tissues, and against other diseases amenable to by F ~ uLlUOi 1~ delivery to tissues the cells of which display 6M1 ,~c~l a.
SpeL;I 'Iy, the present invention discloses a c~-"~, for delivery of ~u"-,i ' pOI~llu~.leGlhle5 to~~ 20 various cells o~ L~al~.. The invention.. ,;;aea a binding protein andO a r".~.i ~ ' pG~ 7lid~. The protein l of the c , - has the property of r~e~,: ;..9 and binding to d~l~l. of many ~ ebldle cells.
lt may further have the property of protecting itself and other ' ' with which it is a~,oc~ d from rapid d~O~dddliun within the body of the animal. And, being a,so ~lPd with a ~L.,Lliolldl pol~ ' -6dL, the binding protein has the ;lllyullal~t property of delivering the pal~,,uLleuli,lO to target cells.
The present invention ~ I . ' le~ the use of any protein capable of ~ binding to or assoLiali.. 3 with any of the several neural or mucosal tissues, including dendritic tissues, tissues of the 9dall l~aIi"dl tract, the IL~ ' _- _ tract, r ~ ~ r airways including lungs, nasal sinuses, and the L~ ~;.a of the eyes. As . ' . the following proteins are all known to bind mucosal tissues: bacterial toxin ' binding subunits including, at a minimum, the B subunit of cholera toxin, the B subunit of the E co/iheat-labile ~ rUtrjAill, Eordetella 30 pertussis toxin subunits S2, S3, S4 andlor S5, the B fragment of ~i, ' ib ia toxin and the l"~:"~I"ane binding subunits of Shiga toxin or Shiga-like toxins.
Other m"ros? ~ ., subunits include the bacterial fimbriae proteins E. coli fimbria K88, K99, 987P, F41, CFAII, CFAIII (CS1, CS2 andlor CS3), CFAllV (CS4, CS5 andlor CS6), P fimbriae, or the like. Other fimbriae include Bor~ '1~ pertussis ~i'_.. . h...aOO' i . I/ibrio choierae toxin-cu.~,' t~ pilus (TCP), mannose-sensitive 35 k~ ~gJlni (MSHA), fucose-sensitive ' ~,O' i ~FSHA), and the like.

A~EN~
IPE~P

7- ~ ' Still other mucosa-binding " ~ include viral allachn~r"t proteins including influenza and Sendai virus he",dyylui' - and animal lectins or lectin-like IIIL'e~ ' ~ including immunoglobulin mm~Aculps or ~rdylllrllla thereof, calcium dPpP~ nt (C type) lectins, selectins, collectins or Helix pomati~ hemagglutinin. Plant lectins with mucosa-binding subunits include concar,av '' A, wheat-germ agylul' ' phytohemagglutinin, abrin and ricin.
Other proteins that can aprL;~ recognize and bind to neural, mucosal, or other ~ell~bldlri cells are cunl6lll~uldled in this invention. Speci~i,ul1y, any i" ir.~g'~t '' having an affinity for d;~li"tlN~ mucosal epitopes, such as the GM1 receptor, is part of the mucosa-binding protein cornponPnt co~ ""~6led in the present invention.
Ad~'t'-- 1'~, lu '' l, chimeric, or Ullldl. ;ad er~y;"re~ed proteins po~sPs: Iy the property of binding to mucosal cells may be used.
In a preferred e L~l lil l of the i"~,.",i' . the mucosa-binding protein is the cholera toxin of l/ibrio cholerae. This L lil I conld,,,,uldl~s the use of the holotoxin, which consists of A and B subunits, and also cout~,,l,uldles the use of a fragment of the toxin, Cu~ lg only of the B ~binding) subunit ,,~onulllrla either singly or in Illullilllrla.
The invention is further embodied in the use of the A ~active) subunit of CT or its analogs as the protein 15 C ~ Ol,~l t of the cr,~l,os;li.~ This aspect of the invention c~r,l~""Jlal~s the use of only the A1 fragment, or only the A2 ~ ', as the protein component of the present invention. Ad'"-- 15~, other enzymes, hGlll..,...,s, COidLIula, or catalysts that, like A1, possess ADP-RbG~laliù,, activity or aid therein, also embody this aspect of the invention. The invention further to~le"~ulales use of d~.i.dli.~s of the cholera toxin, whether natural or synthetic, including all or part of either subunit.
20 ~ ~ Another ~nhG~ n~ the invention has as its protein Cv ~ ùl ~ ~ an i" o~lut_" capable of a~ut~ n!5 ecG~, ;..9 mucosal cells. In a more pd~ .ula, ~ ' '' l of this aspect of the invention, the il""~u..s_' ' '' IrCG9~ ~ C and binds to the GM1 receptor.; 19' ' '' raised against other dr~rll ~s of mucosal cells are also cu~r",,uld~ed in this i"~ni' The binding and toxin ,u~uu~ S of the cholera toxin are well known in the art. Many other proteins with -' 9~ binding plu,uLIlir.~ are also known. Still ûthers can be rllyilleelod. Likewise, ' o~lLt " - against GM1 or other specific epitopes of mucosal cells can be raised.
Further . bc '' la of the invention relate to the pol~,,uLleJ~iJe CG ~ onelll~ In one bt'' ~, the poly"uLl,duGde is DNA. Where the pGI~lluLl~ûlidd iS DNA, the DNA may be of genomic origin. Genomic DNA can be DNA with or without introns, and with or without promoter se9vru~e$~ enhancer ~y ,enre$, and other cis-acting elements. Genomic DNA may also include DNA of genomic origin which has s~d ~eul ~ lly been Illald,Julàled by recu,. 1,' ~ l DNA ie~bl ', -- Genomic DNA may be originally derived from animals, plants, fungi, protists, or bacteria.
Alternatively, the DNA may be cDNA. For purposes of this invention, cDNA may be directly made from mRNA via reverse l,dnsc,i,ulase, or it may be cDNA-like -' ' ~ where the DNA is not made from mRNA with reverse l~dnsL~ laae~ but rather is '. '; ~d to remove introns and to add or remove other seu,~lrllce5 such that the product of the I '. ' lions has the general chd~dLl~,ialiLs of cDNA.
lENl~E{) ~E~T
lPE~P

~ _ _ _ _ _ . CA 02227871 1998-01-26 ~ 8- ' '', ' Ad''~'s--11y, acLo,u', to the invention, the DNA may be re~ ' ' t DNA. For purposes of this invention, ,~c L' l DNA may be any DNA that has been subject to l~ ' ' liùn by re~ - '' ~ l DNA ld,,h"i4.,J~. Such i,~ , 3' may inciude, but are not limited to: random ~u~ r~e~;a sitc ~ led ",ul~9ane, N 3' or 5' RYn,..l.lea,e trimming, linker addition, ligation with other DNA sequ~u~e,, Ill~ ldlion, d~ lhyldliulu polyad~"yidttu", insertion S of a foreign fragment, and removal of an e-~c~, fragment.
The DNA may also be random ~Idylll~nls of DNA. For random ~Idylll~llldliui1, the initial DNA may be a selected amplified sample of DNA, or it may be a random sample of genomic DNA.
ACCGrd;"YI~, the pûly,,ul.lLûlidd component of the invention is not limited only to s~ n~es that encode protein products. Any fl -:iuual DNA sequence is r '~ ,' led, without reference to the length of the molecule 10 in base pairs, and without reference to the physical structure of the molecule. Therefore, whether the DNA is in plasmid form, either ~ " ' or open circular, collcdldlll~li." linear, single-stranded, or double-stranded, the invention cGIll~lllpldla~ any ~u"..t' ' DNA sequence as the pol~l,uLl~u~id~ CG r~ ' This aspect of the invention has as a preferred . Scl' : DNA that contains a promoter region and a coding region. Where there is a promoter region, pl. lela of any origin are culll~ JldlLd.
Coding regions may specify a palli.,~ldl p- 5~ . Such coding regions may include introns or may be without introns. In addition, other kinds of coding regions may be used. Examples of other kinds of coding regions are , u that encode an antisense message or , r S that co"sli~ targets for DNA binding proteins or other agents of i.-l~- 1L ' ~ i~leld~liv~
When the coding region does specify a ~ ,_,,lide, the invention . I~ s all forms of coding regions, 20 both naturally occurring and l-~ bi l. The s, ~ss may be derived from random or sitc ~ Lled or they may be non-mutant ~e~ \.eC They may also specify various protein ~ Jcll..e;. and domains, such as helices, sheets, signal peptides, transit peptides, targeting domains, retention domains, I~y~LLp~~' domains, h~d~.,'"' domains, fingers, ~ippers, loops, coils, active sites, binding sites, processing sites, cleavage sites, o''~, iLali~n moieties, and the like. They may also specify random ~, of known or predicted protein 25 ~ ~e s This aspect of the invention is further embodied in DNA derived from a virus. Such DNA may be directly purified from a ONA virus or may be purified from a viral host, whether r ' yLJIi~. or plû~al~uliL In addition, the viral DNA may be ~1llDl~aiLed in vitro. For purposes of this invention, viral DNA includes any DNA molecule of a virus or derived from a viral RNA or DNA selluProP whether the sequence is complete or only a portion or fragment 30 of the sequence is le~,.e.~ d.
Another preferred; bc " I of the invention has DNA that encodes an antisense message. For purposes of this invention, an antisense message is any pnl~ ul;d~, sequence capable of ~ , ' laril~ assor.:-li. g with other p~l~nl~LleGlid., s. l ~res that would Olhd~ e be ll~n,ht~d, or would assist in lldn~ldtion. This definition Lr~r~ paC5as p Ntl.ULl~otilJds that can form an antisense hybrid with, for example, MRNA, tRNA, rRNA, or other RNA
35 -' - 'os, regions of RNA '~ ' . or other active pcl~l.uJ,col:dus. The essential nature of such anli~nse AMEN~E~ IE~T
IPEh~P

Y . '..; .-",Pss~ges is that they are se~n~",es capable of binding to other polynucleotides and either eliminating or all~uiJdlillg their ~lai1sldliun or other r~lraaiùn or activity. DNA encoding an antisense RNA may aiso be used.
In another Pmhodilnrl l of the invention, the poly,,ul~leulide cuu~,uonrlll is RNA. All ~ullLliunal forms of RNA
are corllrllluldlrd in the invention, regardless of origin, structure, ~uu~ alions, or method of ~JuR~i~.ation.
In a preferred elllb I - 1, the RNA is MRNA. For purposes of this invention, MRNA is any RNA lldlls6lrd or capable of being lrdnJdled to create a pol1l,e,uli-lr product. Therefore, MRNA can be purified from cells, either euhd,~uli-, or prokaryotic, or it can be S~lllh6a;~l3d in vitro. The invention co"le",,ula~es MRNA 'e ' - with and without l,lGd;~iLaliuns affecting el~ ;rllLy of ilcms;diiull, such aa, fûr exampl~i, po',~de;;y!d!iun at thP 3' Rnd or a 5' m'G cap. In another preferred E" ho ' , the RNA is antisense RNA. For purposes of this invention, antisense RNA is any RNA sequence capable of cv, ' La,;l~ binding with other pûN~IluLl~duliJE se.~u~es that would ull., .~ iad be lldllalalrd~ or would assist in ll '. This definition e ~ a~ses p~lyllu~.lruli~lda that can form an antisense hybrid with, for example, mRNA, tRNA, rRNA, or other RNA I -' ' regions of RNA ~' ' s, or other active polyl-u..l~Glidda.
This aspect of the invention is further embodied in RNA derived from a virus. Such RNA may be 15 directly purified from an RNA virus or may be purified from a viral host, whether eukaryotic or prokaryotic. In addition, the viral RNA may be synthesized in vitro. For purposes of this invention, viral RNA includes any RNA
molecule of a virus or derived from a viral RNA or DNA:, ~e whether the sequence is complete or only a portion or fragment of the sequence is Ir.,ulrs~lllOd.
In an 3d~ _ IJc' 1, the RNA is a ribozyme. For purposes of this invention, a ribo~yme is any RNA
20 mo~cule with a catalyt!~ activity, whether aull,calal~ . or hELelu~.dlLl~lil,. The use of any ribozyme as the pol~"u-.leui '- cc...,o L of the c ~,nGsili, of the invention is cGIll~ Jldled herein.
Other forms and cG..~u..,.dLiu~a of RNA are also part of this ;,.~.,..: As PY- 1f the RNA may be rRNA, tRNA, hnRNA, single-stranded, double stranded, self . - ' d, looped, or cu..cdtdlllrlil..
Ar'' - ~r 'I~, the r N~lluLleulild C_ r I of the invention is embodied in any D --~liunal poly..u~duûi ' ~
25 that are not listed above, whether existing in nature or synthetic. Examples of such pOl~llul.lrulidds cGIllell.~Jldll,d by the invention are: linkers, genes, ~JIlJ,.lulrl~, introns, enhancer seu, r~ces~ silencer se.~ es, t,_ ,o '' elements, RNAIDNA hybrids, RNAIDNA chimeras, DNA ~ CGn~ E~ ..u..leùtide analogs, RNA corii li llu"l~uli.ld analogs, hr~ ., ~ mixtures of different DNA Se~lur ~es, helelugrn~ùlJa mixtures of different RNA
,e~ "~es, and hrlril-3 -o mixtures of both DNA and RNA seg,~
The , . - may exist in several useful forms. All useful forms of the co, ~I G. Iiun are cû"lr.,l.~laled in this invention. In one L~r' l, the c~ uoc;l; n exists in the form of an atomized di~,r,.s;u.l for use in delivery by i..l.ahliun. The atomized d;~rla;on may be a solution of the c- - of the invention, or it may be a - -r ' Cuula;ll;uEI the co,~uos;liun. Typical carriers for atomized or d~:lus~ rd di~urra;ùllas include MiglyolB', Frigen~ l1111211131114), and buffered saline. The delivery of the cu ~pcs;l;orl of the invention via i"l,ahl;un has 35 the effect of rapid d;~ue~a;ù~ to a large area of mucosal tissues, as well as absu,pliun by the blood for l,bLuldliun of the c , of the invention to other GM1 cells of the body.
AMEN~D SHEET
IPE~P

. CA 02227871 1998-01-26 In a preferred bcl l, the c , ls n exists in the form of a, I ~o~;lo-y, whether rectal or vaginal.
Typical carriers for t~ lulalion of the inactive portion of a s~lppository include poly~ le,.e glycol, glycerine, cocoa butter, I ~ c~.~ H, and Witepsol'~' H. Other ~ 9~PGS;~ fulll~aldliùlls suitable for delivery of the cG,..I)o~,liun of the invention may also be used. ~elivery of the CO I GS I; II of the invention via suppository has the effect of contacting a mucosal surface with the co l;~G~;Ii Ol for release to proximal mucosal tissues. Distal mucosal tissues may also receive the cu a,r~i(io,~ of the invention by diffusion.
A~ 'Iy, the invention cuui , ' ~ the co ~,~c~i~ivr~ existing in the form of a liquid. The liquid may be for oral dosage, or for û~Jhi' ~' or nasal dosage as drops or for use as an enema or douche. When the composition of the invention exists in the form of a liquid, the liquid may be either a solution or a c ~pPu~ rl of the . - n~ There is a variety of suitable tullllulal;Ons for the solution or "~pP c ". ' r ~ on the intended use thereof.
Delivery of the c~ ~O~IiO,I of the invention in liquid form via oral dosage has the aim of exposing the mucosa of the ga~ ali"al tract to the co- ~ . s;li-~ - A suitable dose, stabilized to resist the pH extremes of the stomach, would deliver the c ~I G. Iiu" to all parts of the gaallL l~li"al tract, especially the upper portions thereof.
The invention c ,' lts all means of: '" the crl pc in a liquid oral dosage such that the effective delivery of the c , ~ could be evenly ": Suled along the ga ,ll, le;~lillàl tract. For example, a coated or c~ release material can be used to release the ~ ~p~ n only after it traverses the stomach. For oral adm;.,;~.l,ali~n in liquid form, the - pr could be thus coated in fine particles and be ~ lod as a Delivery ~e he co ~p~:li l of the invention ~ liquid form via ophthalmic drops wou!d be with the aim of exposing the mucosa of the eyes and ~,o~ Pd tissues to the c -s A typical liquid carrier for eye drops is buffered saline ~ " Methocel~ 65 HG 4000.
Delivery of the o ,- - of the invention in liquid form via nasal drops would be with the aim of exposing the mucosa of the nose and sinuses and assG~,;àl~d tissues to the c , Liquid carriers for nasal drops are typically various forms of buffered saline.
The invention is further embodied in the c~ ,, in the form of a cream for G~Jb~i' ' ', nasal, vaginal, or rectal admi";..ll ~i The use of the c ,- of the invention in the form of a cream applied to a given mucosal tissue has the aim of ti"g the C~ ?r~ on with the mucosal tissue for a auttiL;~"l time to allow the effective delivery of the c - to the tissue. The cream may also have ~ of ss' ' " ~, mucus or 30 olh.,.~ ;je ~ , the effect of mucus as a barrier to delivery of the c r~ Ad~litirn~MI,ucol~li.. ayents such as DNase solutions may also be added. Typical creams and . use as carriers paraffin oil, Pt:llUIdlUIII~
glycerol, pGl~lh~l~ne glycol, ~I~~rt~ glycol and Methocel~b The invention is also embodied in forms of the c~ ""iàtl: for topical ap~lic, I r, or l,a"sde""al delivery to dendritic and other cells. Cu..l~ J6led forms include ua"ad~ll"al patches, creams, and Gi..llll~lll~.
35 Tlàllsdellllal delivery has the aim of releasing the C.~ ,c~;lh"~ either rapidly or gradually over time, to cells proximal IPEAf-P

. CA 02227871 1998-01-26 ~ . . ~ ... .. ..

to dermal tissues. Such cells include dendrites and other nervous tissue, blood cells, and smooth and striated muscle cells.
In another emho~;r.A,ent of the invention, the composition exists as a solid tablet or in a capsule form, for oral dosage. The use of the c~.."i~o, liu~ in this form has the effect of delivering the cQmro~ition to the 5 gas~,ui"lesli"al tract for exposure of the intestinal mucosa to the cu,,,po~;liun. AccorJ ~ly, the tablet or capsule may consist of a material effective in plul6Llill~ the c~ l,o,;lion from pH extremes of the stomach, or effective in releasing the cormrositinn over time, to optimize the delivery of the co,,~l~Gs;liun to the intestinal mucosa. The enteric coating for acid-resistant tablets and capsules typically includes cellulose acetate phtalate, u,u,u~l~,,e glycol, and sorbitan mon~ t~
The invention also coul6"~l-ldles all ways in which the ml~coC? ' ' ~, protein and the pol~lluLl~uliJe may form the CO l~ j,;l;'Q In a preferred emhodi~nt~ the pol~,.uLl~uli.le and the protein are mixed, without the i"l~"Oùnal ~u~ dliun of covalent bonds between the polyllu.,l~oliJd and the protein. In this Pmhod 1, other illyl~di~nls may be included in the mixture to enhance and stabilize the asso.,;dliu" between the protein and the poly--ucleo~iJc. The proper mixing ratios of the protein r , and the pol~,.uLl~otide cu.",uone"l can easily be 15 L ,- i -'Iy d~ ' d~r ~ ~ on the desired effects of the mixture.
The present ways of stably but noncuv ' lly joining a binding protein and a p~'~..ucl~ulide together include the polyca~; polyly~;..e method and the cationic liposome method. In the p~lyl~i;.. method the binding protein is first rl :, 'Iy coupled to pol~ ;..a. The pGI~ ~ pol~'~ ~ coupled with the binding protein is then mixed with the polyl,ucl~olide. The el.,.,lllJsldli.. ;..lelaclion~ between the pQ1yly~;..e and the nucleic acid create a stable 20 cnmp~)sitp~n that ~oes no~~easily di ~ t and is ~herefore suitable fo~Odelivery to the target cells. Wu, G.Y., Wilson, J.M., Shalaby, F., Cru~ a~ M., Shafritz, D.A., and Wu, C.H. (1991) J. Biol. Chem. 266:14338-14342; Chen, J., Gamou, S., Takayanagi, A., Shimizu, N. (1994) FEBS Lett. 338:167-169.
Another example of the ~c h. ~,~ is the use of positively charged lipids to form li~ -s capable of _I~_IlU~Idi- -'Iy illl~ld~.li..~ with P~1~IIULI~OI;d~;~ The pcl~llu~ ui ~ is mixed with the lipids and 1 s are 25 formed. A Li~"..Llional L pc I of the liposome is then chemically coupled to a ' i.àli~l:d form of the binding protein of the i..._.,i The , - is thus capable of delivering the pGI~ ' liJe to the target cells without the for",aliù.. of any covalent bonds between the polylluLl~oliJ~c and the protein. Mizuno, M., Yoshida, J., Sugita, K., Inoue, I., Seo, H., Hayashi, Y., Kn~ a T., and Yagi; K. (1990) Cancer Res. 50:7826-7829.
In another h-'- 1, the mucosa-binding protein and the p~ IiJ~ are ' ~ coupled to each 30 other. Various linkages are co,ll~..l,uldl~l. As ,' the linkage may be either at the carboxy terminus of the protein, the amino terminus of the protein, or at an R group of an amino acid residue within the protein. The pol~"e 1 .,lil may be linked at the 5' end, the 3' end, or with some ~al~"uLl~otide cGIlro~ alions, the linkage may be internal to the polyll..cleul;dc sPqnPnrP
In another preferred h~ " l of the i....: . the mucosa ~ " ~, protein and the polynucleotide are 35 A ~p~ d together. The ~ S ~l~liOIl means may play the dual role of I I ;, the assoL;aliun between the r- , - of the c~ -\I.u,;~ while also ~ulul~.li,,9 the r - from stomach acid, digestive enzymes, t Al..eS l;~

A~FN~ gHE~T
IPE~P

. CA 02227871 1998-01-26 mucus, or other obstacles to optimal delivery to the preferred mucosal tissue. The great variety of possible Pn.~;s~ means is well known in the art. The invention cG~ llluldl~s the use of any Pnc~ J means suitable for a pd,licula, o,,' lioll.
Another aspect of the invention is a method for modulating immunity in an animal. For purposes of this 5 ;"~, I"GJ~6lilly immunity includes either e~ or ' ' ~ an immune response, or it may also include effecting both ~n~ ul and ' ~ , as ~ s~ed below. The first step of the method is to a~' ~ to an animal in r ' lion a mucosa-binding protein and a poly"uLleuliJe encoding an; ~,oge-- The second step is to express the pol~ lida in the animal, whereby the animal gene,dlGs an immune response to the product of the pol~.J~ ulille.
In one preferred embodiment of this aspect of the invention, the Il10[1UIdliUll is an enhanced immune response in the animal. r1e' ' ~ for 6 ' - l may be lhaldl,l~ Gd by a more rapid immune response than would ollldl- 6e occur. It may also be ctldldt.lG(i~ed by a higher titer of ~9' Sc' after exposure to the antigen.
Adfitinn ~' ,,ha~d..leliali..a may include an increased ~Gaisld"te to a pdibe9 , a shorter duration of infection by a pathogen than would ul' ~ ;ae occur, an increased reactivity to related palhrJgeus or antigens, or increased 15 illrldlllllldtùry response to the antigen. The invention C~--u,~ S that the enhanced immune response may be mucosal or 5y or both mucosal and systemic. ~ -- ! ' O proteins such as CT are known to be effective in delivering pcl~ .l;J~,a for yellGI - an immune ,l re Use of these proteins to deliver pol~,,u,,lLuli'~
encoding antigens is similarly effective.
In addition to the ' -l a of enhanced immune lesuoi,aes listed above, a mucosal --' ' immune 2D ~ response may be ~hdldl,leli~d by an i~reased prl,JuLliuh of n~l~dl;L;Il9 ~;LQ ' including slgA. It may be further clldrdl,lGIiLGd by i"wGa,_d, h: of ~ 19~ ' ' IgE, IgG and by enhanced cell-mediated immunity.
In addition to the ' ~ra of enhanced immune response listed above, a systemic e~ Fd immune response may be ,.hdl~LlL.i~Gd by an increased l,.uJu..G of mGulldli~ill9 ant;t,~'!~ including lr. ~' ~ ' IgG.
It may be further clldldLI~.iLLd by increased ~ Jr of og'ot ' IgA and by enhanced c_llmo~i~ted immunity.
An ~'' ' . ' ' l of this aspect of the invention directs the enhanced immune response to CG~Ill L ,:- An acquired specific mucosal immunity to delG" ~ unique to sperm cells is c" u~ led. Where such an immunity is ~, dlGd~ the animal so ~ !d would react to clear mucosal tissues of sperm cells, thereby dGL,.P ~ the number of active sperm available to fertilize an egg of the animal.In another preferred embodiment of the invention, the IlluJuld~iull is a f- ' ld immune response.
'1e-' ' - for a ~" ~ ~ hnd immune response may be cha,dcl~ ed by a less rapid immune response than would oll,e,~ ;ae occur. It may also include a lower titer of imn~lnog~o~ ~ after exposure to the antigen. Additional, cll~ltll,l~liali-.a may include an increased tolerance of an allergen or related pdlhoy~l\a or antigens, " ' ed or F'' ~ l~-l allergy a~ lla, or down-l~yuldLi~... of i"~6l"",alu,y cytokines. The invention colll~lll,uldleâ that the 35 ' ~ ' ' immune response may be mucosal, or systemic, or both mucosal and systemic.

A~EN~ ~HE{~T
IPE~P

. CA 02227871 1998-01-26 . ... - ~ ~,;v,, The inYention is ~l~r~,dbly embodied in a d ' ed immune response for das~ i"3tion to allergens. The invention cun~ Jldl~s varying degrees of de~n~ dlion.
One example of ~ai~ lion to allergens is the well known rh~ ~ of oral tolerance. In classic oral tolerance, an animal that is exposed to relatively large quanlili~s of a pa~ lil.uldl s ~l ,Ih~CP for example, an alleryen, 5 over time becomes less c'~5 ~ sensitive to the allergen. The oral tolerance thus d~.aloyed can manifest itself both in the mucosal immune system and in the systemic immune system.
The dosage required to develop oral tolerance can be ~;y"i~i,,d"ll~ reduced using mucosa-binding proteins coupled to the allergen. In eAu~,i,,,ellls delivering human gamma globulin (HGG) to mice either via simple oral dosage ~feeding) or with a v ~ protein ~CTB) linked to the antigens, the amount of antigen required to achieve the same level of tolerance to delayed-type hy,url~dllsil;.ily (DTH) (late phase) was d~ oAillldlGly 200 to 625 fold greater with simple feeding than with coupling to CTB. Eul Ihellllùlr~ the delivery by simple feeding was i"~r~ e in diminishing the early phase of the DTH response, while the delivery of relatively small doses via coupling to a mllrosa' " ~ protein was fully effective. Sun, J.-B., Holmgren, J., and Czerkinsky, C. (1994) Proc. Nat. Acad.
Sci. USA 91:10795-10799.
The present invention likewise exploits the capacity of the mucosal immune system to ~ nudlr the body's immune response to certain allergens or other ;~ -.o~ ..c, but not by delivery of protein allergens or ;~ --- ,9. "s lhl:".;..,h,.,~. Rather, this invention delivers active pol~,,ucl~ûliJes to the mucosa in order that the products or the activities of the p~1y, ~' :iJes may play a role in the diminution of the body's immune ru, It is important to note that the p~l~ ' liJes Ihdll.~ .,;. are not the 7 . antigens, allergens, or haptens, but instead it 20 is the pol~Jd,ui ' products, or the other activities of the p&l~uul,k,~.liJ.,s, that ullillld~ly effect the de~ired d'- ;- of the immune response.
Because the pdllil,U6l protein CUI~ O~ --l of the C~J ,p~ :~; has a great effect on whether the immune response is ,~ uJ~ ' n~d toward ~ ---l or ' ~ i . the invention c~ u~ 'r~ Cu~ ~p -:0~ capable of either kind of u~e~ dl; n, as well as -' ' lion of either type of immunity, whether mucosal or systemic.
In another preferred '~' :, the f ' ' immune response is for i ' of organ and tissue Il ,' E~ nonself signals of the MHC I class of proteins are capable of ~ an immune l--r~ . and their genes are therefore ca"d;ddl~ for use in the C~Ul.r5~ liv~ of the invention in order to eliminate or at least di le the immune response assoc;alrd with l~coJ, :~d nonself epitopes on lldn~Jldlll~d organs and tissues.
As a example, delivery of a gene encoding an MHC I protein to the mucosa via & ' with a mucosa-binding protein results in local rA~I~aah~n of the gene in mucosal cells. The gene product, rL ~ ~ nonself epitopes, would normally stimulate a ~;y"iri"d"l immune response. Instead, because of the nature of its l:A~
in mucosal cells, it effects a ' ' ' s~"~ ;ly to the epitopes, which " ' ' al~ il;.;ty iS manifest in both the systemic and mucosal immune systems. Shortly th~l~drld" a lldll~pldlll that displays the same epitopes is placed in the animal, and the immune response directed against the ll~ lad tissue is much weaker than it would A~EN~ St~EET
- IPE~P

ulll~ll ;ae have been. ACL...-IjUYIY, the chances of rejection are deL.~ased, as is the need for -' IdOull of immune-au~J~(e~a;on drugs to the tl.ul~uldlll recipient.
A further preferred L-d I of the invention directs the !'- ~ ~ ' ed immune response to the ll~dLlll~
of an ~. - disease. F " - nonself epitopes are not the only d~l~- Is Irco~: rd and attacked by 5 the immune system. Some ' ~" of the immune system result in a lldJl~rrJ9~ of self as nonself, a p, ~ ' by a mistaken immune reaction against the animal's own cells and tissues. This ph~.o ~r~")~ is the basis for dUi ~ diseases such as, for example, systemic lupus erylll~llldlJ~ type I diabetes, ~hdu~dl~.;.l arthritis, and multiple sclerosis. Where such a condition exists, ~e,~ lion of the immune system to the c~ rd J~. ~ ~ of self cells ' l~ or ' dlt~ the cor~;tio~ Acco,d;.,~l~, the invention 10 c L~ Jldl~s the use of the -t pc ~ - of the invention to treat or cure dUi ~ InP diseases.
Also vv ,' l~d in the present imention is the ~: against certain epitopes of a disease pathogen together with a sin,~'~ d~ i".li.~" to other epitopes of the pat~ogen The effect of such a simultaneous up- and down- I O ' of the immune system is to focus the effective immune defenses on the pathogen so as to eventually control or eliminate it, while reducing l.y~ld~ l tissue" damage due to I, ~ d ~;.
15 collateral ;..r . In cases where different epitopes stimulate the cell-mediated immune response on-one hand and the injurious " : y response on the other, the disease can best be treated by s~ c I~Gdu6i of the immune response toward greater se~;l;.;.y to one epitope and much less n .~ ~.-,.-_5S to the other.
According to the ..: . the d~!i.: of the immune response may be prior to exposure to a pathogen or allergen. Examples of 9" ' of the invention using ~ A~G3~I-Dd~ include v c; .
20 ~e~rn~ i . and p~b~u~JIiv~ ~u~c -1~
Where a pathogen is known, and v. ~ ~ :- against the pathogen is desired, a gene encoding an epitope of the pathogen is delivered as part of the - pr of the ~..i The gene is i..l~.. ' d and eA~ ..sed within mucosal cells, and an 6 ' ~ i immunity of both the mucosal and the systemic immune systems results. Suh,~
exposure to the pathogen is met at the point of contact by a strong and specific mucosal immunity as well as 25 systemic immunity. The ~r~GIi.. of the pathogen as a disease causing agent is thus reduced or diminished.
The invention also c , ' the modulation where it occurs after exposure to the pathogen or allergen.
Examples of 9, r~- - of the invention using pQ~ ' ' - include pv -- ~ for chronic ~ ',: : to create an ~ reaction to cancer cells, d~ dll........................... l for allergies, and to epitopes attacked in : disease.
Where an . - ~ disease has been ~; g,-~se~ and its basis is _ ' ~c-d, a p~ .. ucl~,liJe encoding the epitope being ~LG~ ~d as nonself by the immune system is c ,' ' or oll.~.~ ;ae combined with CTB.
The c . - is fed to the animal in an ~,, ., iale dose, which results in !'- ~ ~ ' ' or " L~d mucosal and systemic immunity against the epitope of the dUi ~ disease.
ALC~ , all uses of the of the invention for the od ' i lr. of the immune response are 35 embodied in the present invention, whether iJIL~A~u~lJlt or pGsl~A~JGaul~ and whether to immunize or de~ r the animal so treated.

l~Effp The cuu~ ion of the invention may be e ' dd in a number of ways. In one ~ od~ , the mode of ad ~.dliUII is nasal. ~r~ IdliOII of the cG,~nos;~i n of the invention nasally has the aim of exposing the mucosa of the nose and sinuses and as~uLidl~d tissues to the co~rosition All~llldli.Lly, the invention is also embodied in a mode of -' : i"g the c Inos;l;m of the invention by illbdldliOn. A~ dLion of the 5 c~ pû,;li, of the invention via i"hdldlio" has the effect of rapid .~i~p~,~;ùn to a large area of mucosal tissues, as well as abso"uliùn by the blood for cb~.uldliuil of the cv, ~I~Gc;li~n of the invention to other GM1 cells of the animal.
The invention is further embodied by ~' ~: b~y the c~ n ophi' ' -11y. ~ ~ ;ldliùll of the c~",uG~;~ion of the invention ~"~hih~ has the aim of exposing the mucosa of the eyes and associdled tissues to the C - - r ~ ~
In a preferred e~ - --I, the mode of - ' .. dliun is oral. Al' ~ lldliuo of the co",l\o~ li n of the invention orally has the effect of exposing the mucosa of the gasl~ li"al tract to the CG~ JGs;liu". A suitable dose delivers the Cv-~l-G~ o to all parts of the gd~l-l Idslb~al tract. The invention cGnl~lllulal~s all means of oral delivery, whether in a liquid oral dosage, as a solid tablet, or in a capsule form.
Further preferred eulllGl~ l ~- the c l~pu,;lioll of the invention rectally or vaginally.
15 ~I' ~ '.dliull of the co ~",5;1; ~ of the invention rectally or vaginally has the effect of cvul. Ii- y a mucosal surface with the cr-r~ for release to proximal mucosal tissues. Distal mucosal tissues may also receive the c ,: of the invention by diffusion.
Another aspect of the invention is the ~L , tllllLi _ to deliver a pr,l~,,ucl~uli le to any GM1 animal cell. Where the binding protein L , of the composition has an affinity for the GM1 receptor, the r , - ' -20 could be delivered - ~ any cell d, ' ~;"v the GM1 recs~to~. .
GM1 v ' - ' is found in the plasma l"~"iL. - of cells 0ll uu,vllGul the body. However, the CollC~ d;
of GM1 in the plasma ",~",br of different cell types varies ~;y"i~iLd~ . Only in cell types with a certain critical level of GM1 tonc~"l,dl;on does GM1 actually act as a receptor for binding CTB. Different binding proteins interact with GM1 or dyyl~ydle~ of GM1 in different ways. This fact allows a person 1-- - _ the invention to design a 25 gene therapy ~ r capable of limited targeting of a t' ,.~,.,..IjL gene to mucosal cells, or more general targeting to other cells Fcss~ , a certain concL..Irdt of GM1 in their ! b~. 9~ This mode of delivering h~lù~ iL genes therefore allows a degree of precision in selecting target cells not ,J~b-;.JU~ available.
The present invention cGrll~llluldtds the use of any protein capable of ~JeLiri 'l~ binding to or dSsuL;dlillg with GM1 cells. For purposes of the invention, a GM1 cell is a cell of a ~ Lldl~ animal having g_ _' ' GM1 30 in its plasma ",~",L.dne. Many of the proteins already listed before as mucos o ! ' _ proteins are either known or believed to bind mucosa via the GM1 receptor, and are therefore also suitable for use in this aspect of the ..C Likewise, all of the kinds of p.~l~llucl~uli '~ d; ~ d above are also a~.~".r id~d for and cor,l~ p'-lPd in this aspect of the invention.
The delivery of the c~ ~u~ of the invention is not limited to mucosal cells alone. Many other cells 35 display GM1 in varying cGr,ce,,l~dliu,,~. For example, neural cells are known to have high conL~"I,dliùns of GM1.
Other cells whose surfaces have lower collL~ulldli~.as of GM1 may be primed for delivery of the composition of the ~I~EN~ ~EET
IPE~P

.. .... . - . ...

invention by ,u,u;,,Lubaliùll with GM1 followed by a si '" period, then finally followed by dosage of the cu""3Gs;liun of the invention. Cells with different Illcu,lJ~dne cGIllpollcllls will have varying degrees of affinity for and rates of uptake of GM1. Acco, " ~, the invention can be practiced in such a way as to regulate the time and other con~ c of illbubdliv.., together with the conLc,ll~dliùn of the ~.ogr"au. GM1 and the time of : bi" lion, 5 to modulate the crFcLli.~..css of the uptake of GM1 by the target cells and thereby modulate the ultimate dosage of the cu--~poc;'i- n delivered. Thus, any cell type can potL 'Iy be aclcLL..,ly ~,cl,edled to enhance the erri..;c"~.
of delivery of the 'r-- of the invention.
Likewise, anti GM1 antibodies can be used to block GM1 receptors and dllcnudlc the affinity of high GM1 ,...,..~brà"es for the & , ~ of the invention. The invention dllli..;~udlca the use of both forms of ulcllcdllllclll.
10 either with antibodies against GM1 or with GM1 itself, either singly or in s ' ~ :- . to achieve the desired result.

As an example of the use of both forms of plcllcdllllclll~ a tissue co~ ,g of two major ~ ù~(n l'liùn5 of ceils is selected for llcaL.. .~t with the low-GM1 cells being the most preferred target for delivery of the c ~rG~ Iim of the ~ .. First the entire tissue is treated with a solution CGlli ' ~ _ anti-GM1 IgGs at an 15 au~ulopliàlc concc,,l~di The IgGs occupy most or nearly all of the: ooes ' ' GM1 in the ' a"es of the high-GM1 cells. After lavage to remove the excess antibody, GM1 is added to the tissue. Following the diffusion gradient, GM1 will insert into the low GM1 membranes more than into the high GM 1 membranes, and the GM1 thus diffused will be largely free from antibody blocking. After a second lavage to remove non i I-cd GM1, the tissue is ready for dosage of the s pr- of the ;..~. . and specific delivery of the active pol~ ,,lcuGJ-c is effected 2D to the cells tha~ ~ere or;~ally lowest in.GM10 The gene therapy aspect of the invention discloses a method for gene therapy in an animal by r ' ~ ~ j~
to an animal in - ' a GM1-binding protein and a r~"..,lio,lal pcl~,..,,lcoliJc and then cAlJI'caa;ll_ the pGI~Iluclcul;J~ in cells of the animal. By this method, the function of the pGl~,...,,l,,~GJc confers on the animal a Ih~P~ ;L effect.
In a preferred ~ bc" of this aspect of the invention, the cells of the animal llal,a;c"ll~ express the delivered t~ ool~ 'I li'u. Transient -ca~ ~ is Lhdldl~lcli~'cil by an onset of eA,uldsa;un cl,. 11~
followed by a cessation of e..,u,- The duration of c~,u,, ~ is a function of the stability of the active pol~ ' . ' in the cell. Factors affecting the stability of the pol~,....,lcuGJe include: the nature and structure of the pol~lublcoi ' . the subcellular location of the po~rllu~.bculiilc, the d~ , of l ' ' proteins or Iytic 30 enzymes in the local area of the ~el~..JLI~.~li-' and other physical pd,d",clc,s of the cell such as lc~ dlUIc~ pH, and conc~i..lld;- of certain ions.
For many , ' : s, transient -c.~,u,G..a;ù,, is preferred because the product of the delivered gene or the activity of the F~ ' would be d~lulcl- in the long term. Therefore, in such cases, selection of a pr1~,..J.,lculida more likely to be lldlla;cllll~, and not stably, -c~u,cased, will be dpp,uplidl-c. The cl,a,aLIc,iali,,a of ~5 pol~ oti~s that render them more or less stable in a host cell are known in the art, and a person of ordinary skill could select an 3,, , ialc pul~l,u-,lculiJ-c for the pdlli~.ulal practice of the invention.
A~END~ SHE~T
IPE~EP

-17 '. ' .
.. ..., . . '' An all~,l,dl;.~ preferred embodiment exists when the cells of the animal are stably transfDrmed by the lu"cliunal polyll,JcldGtill~ Stable llar,~urll,dlion is characterized by the actual hll~yldliull of a polynucleotide into the genome of the host cell, and sllhse~luent ~x~s~;ùn of the genes or other activity of the poly"ucle~liJe Ihl._o':~_l the life of the cell.
Certain uses of the present invention will neces~;ldl~ or benefit from stable tld~sroll''dliun of the cells by the pGl~l,u~,le.,lide. For example, where the therapy involved is the rrp~ l of a missing or nGIlRlllLliundl gene, stable llauaiulllldliun of the cell would llo~ dll~ cure the defect, where transient ~A~ aaiUa of the pol1llucleulidd would u~cesaildle CG~li' ' O t,~al,ll~"ls.
The ci-ldldl,l~lialil.s of polynucleotides that may alone or in c ' liun make the pGI~-.ucleulide more likely to stably integrate into the genome of the host cell are known in the art. A skilled artisan could select the desired ,hdldLl~lialiLs for the polynucleotide to be delivered so as to maximize the likelihood of stable illl~yldliol1 and Il d~ Illdliùl) uf the host cell.

EXAMPLE 1. Formin~ the CUIII~.J;~
Cholera toxin B subunit protein (CTB) is coupled to poly L-lysine as described ~ iu~lal~ . Jung,G.~ Kohnlein, W., and Fiders, G. (1981) Biochem. Biophys. Res. Commun. 101:599 606. The CTB protein is reacted with a 7-fold molar excess of poly-L-lysine at pH 7.4 using 1-ethyl-3-(3-' Ihy' , .,,u~l) cali.-' ' present at 154 molar excess over poly-L-lysine. After 24 hours, the ; ~ product is purified by chr~llldloy,_ h~, and titrated with plasmid DNA using a gel retardation assay as described by Wu. Wu, G.Y., and Wu, C.H. (1987) J. Biol. Chem.
20 ~ 262:44294432.o The DNA:~otein co~plex is then used to fosm a CL~ C~ I; " app,."idl~ for the preferred mode of delivery.

EXAMPLE 2. M ~ ~ l~
A DNA sequence cu,, O a strong promoter and a coding region encoding epitopes of the A8 and VDIV
proteins of Ch' , ' ll ,h li~ is c , ' ~ with CTB by the pGlyl~ method as ~1; - v~d above. A small amount of Cholera toxin A ICTA) subunit is included in the cn m~û~ as an adjuvant. See Czt:H i~ky, C., and Holmgren, J. (1995) The ~ r~ ~' 313:97-103; and Allen, J., Locksley, R.M., and Stephens, R.S. (1991) J.
Immunol. 147:674-679. The c~ is delivered once via vaginal ~ llGSPl\~y to ~' , ' free ~ . A
C~ ; ' free control group is given a placebo, ~npc~ n., y. At six one-week intervals, samples of serum and vaginal mucus are taken from i ".;.h,a'5 of both groups. ELISA assays on serum samples show the presence of IgG specific for A81VDIV in the t,edl"-~nl group and not in the control group. Similar assays on mucus sampies d~lllun:,lldl~ that the ll~dl..._..l group has a high titer of slgA specific for A81VDIV while ". ' ' of the control group show no such reaction. A s ' ~ ..l historical study of both groups shows a lower incidence of t-'/' ~/J;O i"ie~lions among members of the ll~dllll~lll group compared with members of the control group.
EXAMPLE 3. ~--' ' ' ' ~l~n Reduced 1-" : y R~, e A \/lEN~~~ SHEET
IPE~P

. < . . . ~ . . . ' ' . . ' . ' :
A DNA sequence cu"i a strong promoter and a chimeric coding region encoding a fusion of both CTB
and the heat shock protein ~HSP 57) of C~ /id lldC~ldilldt;.~ is Gom~ with CTB protein by the polylysine method as d;~ ~cad above. The cU~ 1~~~ n is delivered once via vaginal s~rl~Qcitory to patients sufferiny from Chl~, J/i i,,~.liuns and pelvic il,rla"""dldry disease (PID). A control group of similarly infected patients is given 5 a placebo ~u~,o~;~u.~. At six one-week intervals scratch tests and tine tests are pe~tu""ed on the forearms of i"dN;duals of the two groups using whole ChlamJ~di~ Iysates. 'i-;d~.~ s of the two groups are also surYeyed for d~ liun of the severity of PID a~ Jlulll~. The IlLallllLnl group displays a markedly ed 5~lla;l;ll;ly in the scratch and tine tests, as well as ' d S~ lull~ of PID. The control group shows no such results.

10 EXAMPLE 4. r ~ t~,. S ~ and Reduced ~ y n ;e A vaginal ~ ' y containing both the ONA -tlUL~ from Example 2 and the DNA r-a~ ~.u,.l from Example 3 is ~ ~ ~~tPred to ~' : a infected with C~' ~Ji. A placebo ~ lu.y is . ' ~: ~d to an GLIl~ d similar control group. The individuals of the ll~ai I group ~ H~nce both d~ as~d s~ .r of PID
and e "- ~e~ c..ll. "'~"tPd immunity to C!' 1dia. Mucus samples show high titers of slgA and IgG against A8NDIV, but very little reaction to scratch and tine test using whole ChlamJ~di~ Iysates. The collateral DJ_: ' tissue" damage that is chdla~ lic of PID is therefore l~ There are no culll~làl ~ results among members of the control group.

EXAMPLE 5. T~' of Or~an T. .' A set of ~- : DNA plasmids is s .u~le;l each ~ ~ DNA encoding one of various MHC-1 proteins under control of a promoter. The resulting plasmid bank is chald~ ed and ' ~ d and batches of each plasmid are :l 1 with CTB using the pol~ method as described above to create an organ t H ~ i~ai~ ~ I,. I bank.
An organ donor is screened to d, l~, her MHC-1 gcaGIy~ The results of the screen are matched with the d~upn, ;ale tH __ C , q from the bank d;~ s~d above.
A patient about to receive the donated organ is given doses of the '~ c~ ~o~:li-"~ as an atomized di~ Ia;.~il via ' li., " as a rectal, ~l I o~ and orally as an enteric-coated tablet. The patient develops a rapid oral; ' a,lce" to the foreign MHC-1 protein and displays a mllrh :" ' ~ ' e1 nonself ,, 1r. of the donated organ. Because of the duration of e~nJI Lsa;ùl) and the abundant ~ ~ of the nonself MHC-1 gene in the mucosa-ass~cialed Iymphoid tissues (MALT), the acquired tolerance is more long-lasting than would have been the case with any more cu"~: ~ approach to oral t '~ i~aliuil using the MHC-1 protein itself, rather than the gene.

EXAMPLE 6. T-._ I of an A l Disease Patients suffering from an autH ~ form of diabetes are orally ' : td a cnn-position C~Ua;alill!a of a chimeric gene encoding both CTB and human insulin under control of a strong viral promoter wherein the DNA
of the chimeric gene was ' with CTB protein by polyl~s;lle as described above. The chimeric gene is ~I~EN~ StlE~T
lPE~EP

delivered to the intestinal mucosa where it is hll~lllaii~d by cells of the MALT. These cells express a chimeric fusion protein conc;~liu9 of CTB and insulin, which in combination effect a tolerization of the mucosal and system immune system to the insulin epitopes. The patients' dulo:m.l~uiiy to insulin is " ' ~d and the progress of their diabetes is slowed.
Other, non-lidbeli~., patients palli~,;,vdiillg in a long-term study are also ~ ' i~l~d the cGIll~.osi~ion. The ,e.~ " onset of diabetes among the voluul~ is lower than among individuals of an u~hdnl~ise similar control group.

EXAMPLE 7. Gene Therapy A cvl,~,o~il; n is prepared col~ !J of LTB and non mutant mRNA cGI~pon~ to the mutant gene that is cauad~ of cystic fibrosis (CF). The cu~ o~ n is ~ ed twice daily to CF patients both orally and via ildldldi The Co-~pG~ is localized to the mucosa of the lungs and the gdal~ ;llal tract where the enzyme for which the CF patients are deficient is ~rliLi~ and lldll~i~nll~ produced. The ~lu~Jlu~ of CF in the patients thus treated are much di Ai~EN~ED S~EET
IPEA~EP

Claims

WHAT IS CLAIMED IS:

1. A composition for mucosal delivery of a polynucleotide comprising:
a mucosa-binding protein having an affinity for determinants of vertebrate mucosal tissues; and a polynucleotide in association with said binding protein, said polynucleotide encoding a product which produces an enhanced immune response.
2. The composition of Claim 1 wherein the mucosa-binding protein is selected from the group consisting of CT, CTB, LT, bacterial fimbriae proteins, animal lectins, plant lectins, and lectin like proteins.
3. The composition of Claim 1 wherein the mucosa-binding protein is selected from the group consisting of cholera toxin and its derivatives.
4. The composition of Claim 1 wherein the mucosa-binding protein is an antibody.5. The composition of Claim 4 wherein the antibody is directed against the GM1 receptor.
6. The composition of Claim 1 wherein the polynucleotide is DNA.
7. The composition of claim 6 wherein the DNA is of genomic origin.
8. The composition of Claim 6 wherein the DNA is cDNA.
9. The composition of Claim 6 wherein the DNA is recombinant.
10. The composition of Claim 6 wherein the DNA contains a promoter region and a coding region.
11. The composition of Claim 1 wherein the polynucleotide is RNA.
12. The composition of Claim 11 wherein the RNA is mRNA.
13. The composition of Claim 1 in the form of an atomized dispersion.
14. The composition of Claim 1 in the form of a suppository.
15. The composition of Claim 1 wherein the mucosa-binding protein and the polynucleotide exist in the form of a mixture.
16. The composition of Claim 1 wherein the mucosa-binding protein and the polynucleotide are chemically coupled.
17. The composition of Claim 1 wherein the mucosa-binding protein and the polynucleotide are encapsulated together.
18. A method for enhancing immunity in an animal comprising:
administering to an animal in combination a mucosa-binding protein and a polynucleotide encoding a product which produces an enhanced immune response; and expressing said polynucleotide in said animal whereby said animal generates an immune response to the product of said polynucleotide.
19. The method of Claim 18 wherein said modulation is an enhanced immune response.
20. The method of Claim 19 wherein said enhanced immune response is mucosal.
21. The method of Claim 19 wherein said enhanced immune response is systemic.
22. The method of Claim 19 wherein said enhanced immune response is for contraception.
23. The method of Claim 19 for preexposure vaccination against a selected epitope.

24. The method of Claim 19 for postexposure enhanced immune recognition of a selected epitope.
25. The method of Claim 19 wherein the mode of administration is nasal.
26. The method of Claim 19 wherein the mode of administration is oral.
27. The method of Claim 19 wherein the mode of administration is rectal.
28. The method of Claim 19 wherein the mode of administration is vaginal.
29. The method of Claim 19 wherein the mode is administration is inhalation.
30. The method of Claim 19 wherein the mode of administration is ophthalmic.
31. A composition for delivery of a polynucleotide to a GM1 animal cell comprising:
a binding protein having an affinity for the GM1 receptor; and a polynucleotide in association with said binding protein, said polynucleotide encoding a product which produces an enhanced immune response.
32. The composition of Claim 31 wherein the binding protein is selected from the group consisting of CT, CTB, LT, LTB, bacterial fimbriae proteins, animal lectins, plant lectins, and lectin like proteins.
33. The composition of Claim 31 wherein the binding protein is selected from the group consisting of cholera toxin and its derivatives.
34. The composition of Claim 31 wherein the binding protein is an immunoglobulin.
35. A method for gene therapy in an animal comprising:
administering to an animal in combination a GM1-binding protein and a functional polynucleotide;
and expressing said polynucleotide in cells of said animal whereby the function of said polynucleotide confers on said animal a therapeutic effect.
36. The method of Claim 35 whereby said cells of said animal transiently express said functional polynucleotide.
37. The method of Claim 35 whereby said cells of said animal are stably transformed by said functional polynucleotide.
38. A composition for mucosal delivery of a polynucleotide comprising:
a mucosa-binding protein having an affinity for determinants of vertebrate mucosal tissues; and a polynucleotide in association with said binding protein, said polynucleotide being capable of regulating gene expression.
39. The composition of Claim 38 wherein the polynucleotide encodes an antisense message.
40. The composition of Claim 38 wherein the polynucleotide is an antisense RNA.
41. The composition of Claim 38 wherein the polynucleotide is a ribozyme.
42. Use of the composition of Claim 1 in a medicament for enhancing an immune response.
43. Use of the composition of Claim 38 in a medicament for modulating an immune response.
44. Use of the composition of Claim 35 in a medicament for producing a therapeutic effect.

45. A method of regulating gene expression comprising administering to an animal in combination a mucosa-binding protein and a polynucleotide capable of regulating gene expression whereby said polynucleotide regulates gene expression when introduced into a mucosal cell of said animal.
CA002227871A 1995-07-26 1996-07-19 Mucosal delivery of polynucleotides Abandoned CA2227871A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US152795P 1995-07-26 1995-07-26
US60/001,527 1995-07-26
PCT/US1996/012041 WO1997005267A2 (en) 1995-07-26 1996-07-19 Mucosal delivery of polynucleotides

Publications (1)

Publication Number Publication Date
CA2227871A1 true CA2227871A1 (en) 1997-02-13

Family

ID=21696500

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002227871A Abandoned CA2227871A1 (en) 1995-07-26 1996-07-19 Mucosal delivery of polynucleotides

Country Status (5)

Country Link
EP (1) EP0840796A2 (en)
JP (1) JPH11510164A (en)
AU (1) AU6505796A (en)
CA (1) CA2227871A1 (en)
WO (1) WO1997005267A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69835525T2 (en) * 1997-03-12 2007-03-08 Idera Pharmaceuticals, Inc., Cambridge DERIVED REGULATION OF GENE EXPRESSION BY COLORECTAL ADMINISTRATION OF SYNTHETIC OLIGONUCLEOTIDES
GB9713122D0 (en) * 1997-06-20 1997-08-27 Chiron Spa Novel method of DNA transfer into cells
BR9914160A (en) * 1998-09-30 2001-06-26 American Cyanamid Co Antigenic composition, method for increasing the capacity of an antigenic composition that contains an antigen selected from a pathogenic bacterium, virus, fungus or parasite, haemophilus influenzae, helicobacter pylori, respiratory syncytial virus, rotavirus, and simple virus of the herpes to evoke the immune response of a vertebrate host, plasmid, host cell, method to produce an immunogenic mutant cholera holotoxin, and use of an effective auxiliary amount of a mutant cholera holotoxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US7041296B1 (en) * 1999-11-12 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating inflammatory bowel disease using cholera toxin B subunit
US7332174B2 (en) 2001-06-07 2008-02-19 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
CN1977971A (en) 2001-06-07 2007-06-13 惠氏控股有限公司 Mutant forms of cholera holotoxin as an adjuvant
CA2479212A1 (en) * 2002-03-15 2003-09-25 Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2010009271A2 (en) 2008-07-15 2010-01-21 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
AU2014317889B2 (en) 2013-09-06 2020-03-05 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI797430B (en) 2014-03-27 2023-04-01 中央研究院 Reactive labelling compounds and uses thereof
WO2015184004A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US11319567B2 (en) 2014-05-27 2022-05-03 Academia Sinica Fucosidase from bacteroides and methods using the same
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
WO2015184001A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
CA2960712A1 (en) 2014-09-08 2016-03-17 Academia Sinica Human inkt cell activation using glycolipids
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
CA2972072A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
CN109195996A (en) 2016-03-08 2019-01-11 中央研究院 The modularity synthetic method of N- glycan and its array
JP7213549B2 (en) 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド Antibodies, Binding Fragments, and Methods of Use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
JPS63258493A (en) * 1987-04-15 1988-10-25 Mitsui Toatsu Chem Inc Anti-ganglioside gm, monoclonal antibody, cell producing said antibody and reagent composed thereof
IL92578A0 (en) * 1988-12-07 1990-08-31 Univ Leicester Heat-labile toxin b subunit fusion proteins and their preparation
ATE99331T1 (en) * 1989-09-08 1994-01-15 Takeda Chemical Industries Ltd FUSION PROTEINS AND PRODUCTION THEREOF.
IL96475A0 (en) * 1989-11-29 1991-08-16 Innovative Tech Center Chimeric proteins
US5433946A (en) * 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
WO1994023752A1 (en) * 1993-04-16 1994-10-27 University Of Portsmouth Enterprise Limited Drug delivery system
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent

Also Published As

Publication number Publication date
EP0840796A2 (en) 1998-05-13
WO1997005267A3 (en) 1997-04-24
WO1997005267A2 (en) 1997-02-13
AU6505796A (en) 1997-02-26
JPH11510164A (en) 1999-09-07

Similar Documents

Publication Publication Date Title
CA2227871A1 (en) Mucosal delivery of polynucleotides
US5985847A (en) Devices for administration of naked polynucleotides which encode biologically active peptides
CA2425745C (en) Expression of exogenous polynucleotide sequences in a vertebrate
WO1995005853A9 (en) Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
AU7639194A (en) Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides
US20170044540A1 (en) Sarna compositions and methods of use
Bartlett et al. Lipopeptide-based oral vaccine against hookworm infection
US11162099B2 (en) HNF4A saRNA compositions and methods of use
JPH06509563A (en) Molecules targeting epidermal growth factor receptors for the treatment of inflammatory arthritis
US7741431B2 (en) Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
BRPI0210568B1 (en) conjugate, use of a conjugate, and pharmaceutical composition
Hagino et al. GALA-modified lipid nanoparticles for the targeted delivery of plasmid DNA to the lungs
JP2003530360A (en) Peptide conjugates for drug delivery
US10206976B2 (en) Protein particles comprising disulfide crosslinkers and uses related thereto
Nakamura et al. Lipid nanoparticles fuse with cell membranes of immune cells at low temperatures leading to the loss of transfection activity
JP2001526181A (en) Graft copolymers as gene transporters
CN110520534A (en) The intestines of programmed death ligand 1 are expressed
JP4820000B2 (en) Verotoxin B subunit for immunization
US20210102204A1 (en) Sirt1-sarna compositions and methods of use
US8679780B2 (en) Method of reducing immunological tolerance to malignancy
JP2002513558A (en) Myelin basic protein peptide and use thereof
Chavda et al. Nanocarrier-based delivery of peptides: challenges and way forward
Yong et al. Stability analysis of recombinant human TFF2 and its therapeutic effect on burn-induced gastric injury in mice
KR20090092536A (en) Composition comprising recombinant adenovirus and liposome with enhanced gene transfer
US20040146526A1 (en) Inhibition of NF-kappaB activation

Legal Events

Date Code Title Description
FZDE Dead